1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Integrum AB Class B

Integrum AB Class B

SSTO:INTEG_B
8.50
SEK
-0.11
(-1.28%)
-1.43EPS
234.14MMarket Cap
Dec 03Next Earn
Integrum AB Class B
STO:INTEG_B
(Nasdaq Stockholm)

Recent

price

8.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
SEK
1.48
1.23
1.99
1.51
1.77
1.67
2.77
3.09
4
5.58
4.16
3.79
3.94
Revenue per Share
- -
-0.01
-0.64
-1.83
-1.94
-0.98
-0.14
1.18
-0.87
0.22
-1.41
-1.92
-1.43
Basic EPS, GAAP
-0.07
-0.42
-0.97
-1.79
-2.01
-1.19
-0.43
-2.75
-1.97
-1.31
-2.29
-2.4
-1.96
Free Cash Flow per Basic Share
0.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.13
0.12
1.18
1.79
1.26
1.48
1.51
8.74
7.69
7.39
8.22
6.45
6.53
Book Value per Share
0.11
0.04
0.99
1.62
1.15
1.4
1.37
7.03
5.44
4.65
5.45
3.95
4.02
Tangible Book Value per Share
10
10
9
10
13
16
16
18
19
19
22
24
25
Basic Weighted Avg Shares
15
12
18
15
22
27
43
56
74
104
91
91
98
Sales/Revenue/Turnover
-5.37
0.56
-35.56
-125.54
-115.01
-60.38
-1.03
-13.36
-34.05
0.66
-45.61
-56.38
-37.96
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
2
7
19
13
Depreciation Expense
- -
- -
-6
-18
-25
-16
-2
21
-16
4
-31
-46
-36
Net Income, GAAP
100
- -
- -
- -
- -
- -
- -
- -
- -
33.2
- -
- -
- -
Effective Tax Rate (%)
- -
-0.86
-32.26
-120.99
-109.5
-58.65
-4.99
38.17
-21.79
3.87
-33.83
-50.71
-36.3
Profit Margin (%)
- -
4
10
15
13
18
20
106
72
62
79
53
56
Working Capital
1
4
2
1
1
2
1
- -
6
5
3
1
1
LT Debt
1
1
11
18
16
24
24
160
144
143
178
172
174
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.9
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.93
- -
- -
- -
Return on Capital (%)
- -
-9.77
-99.24
-128.66
-144.38
-78.93
-8.96
23.13
-10.67
2.82
-19.23
-26.5
-20.74
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Jan'26
Apr'26
Jul'27
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
264
209
234

Working Capital

SEK

•

in mil. unless spec.
Jan'26
Apr'26
Jul'27
Total Current Assets
96
84
80
Cash, Cash Equivalents & STI
30
19
15
Accounts Receivable, Net
26
20
29
Inventories
34
29
30
Total Current Liabilities
22
30
24
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
158.69%
113.82%
-3.18%
Free Cash Flow
86.19%
139.21%
15.45%
Net Income, GAAP
322.47%
-440.99%
50.37%
Sales/Revenue/Turnover
24.85%
18.12%
0.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
18
22
24
27
91
2026
24
22
20
25
91
2027
30
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.48
-0.46
-0.18
-0.42
-1.41
2026
-0.47
-0.34
-0.47
-0.66
-1.92
2027
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Integrum AB (publ) (INTEG-B.ST) researches, develops and sells innovative systems for bone-anchored prostheses based on osseointegration technology, serving amputees worldwide through hospitals, clinics and orthopedists; core offerings include the OPRA Implant System comprising titanium fixtures, abutments and extensions for direct skeletal attachment in S1 and S2 surgical procedures that eliminate socket prostheses, OPRA devices for upper and lower limb applications, and Neuromotus technology for phantom limb pain therapy via electrical stimulation; the company operates in the medical technology sector targeting rehabilitation for limb loss patients, with Centers of Excellence spanning the United States, Europe and other regions. Founded in 1990 by Drs. Rickard Brånemark and Per-Ingvar Brånemark and headquartered at Krokslätts Fabriker 50 in Mölndal, Sweden, Integrum holds a world-leading position with over 500 OPRA surgeries performed globally and ongoing R&D to enhance mobility and quality of life. Recent developments encompass strategic U.S. market expansion driving 29% Q1 2025/26 revenue growth to SEK 23.8 million and 25% increase in S1 procedures to 27 cases, new distribution agreements with Labormed d.o.o. in Slovenia and Bionics Group Ukraine LLC for OPRA implantation units, leadership appointments of Martin Hillsten as CEO in May 2025 and Louise Wåhlin as CFO effective September 15 2025, a SEK 10 million credit facility closure in August 2025, oversubscribed rights issue yielding SEK 42.7 million net proceeds in December 2025, legacy sponsorship of the Global Collaborative Congress on Osseointegration through 2028, and a recommended public acquisition offer from OsteoCentric Oncology and Bone Anchored Prostheses LLC at SEK 44 per share valuing the company at SEK 939 million with acceptance period ending mid-September 2025.